Abstract
After successful treatment of childhood malignancy, development of second malignancy (SM) is the most devastating and potentially life-threatening sequelae of it. In the past 12 years there have been no cases of therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) among 80 children treated for soft tissue sarcomas (STS) in the Department of Paediatric Oncology, Haematology, and Bone Marrow Transplantation. Given the rarity of recognition of t-MDS/AML in children after treatment of cancers, it was decided to analyse in detail the therapy and cytogenetic and molecular results in two boys aged 9 and 10 years old, diagnosed with t-MDS/AML secondary to rhabdomyosarcoma. In both of them TP53 mutation was found. Palliat Med Pract 2020; 14, 1: 58–62
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
